PDS Biotech is a clinical-stage immunotherapy company developing targeted cancer and infectious disease treatments using its proprietary Versamune® T cell activator platform and Versamune® combined with an IL-12 fused antibody drug conjugate (PDS01ADC). The Versamune® platform uses lipid nanoparticles to stimulate dendritic cells and trigger robust CD8 and CD4 T cell responses against disease-associated antigens, while PDS01ADC enhances T cell activity in the tumor microenvironment and reduces immune suppression, with the combination designed to work synergistically with checkpoint inhibitors. The company is advancing multiple product candidates in oncology, including lead candidate PDS0101 for HPV-related cancers and PDS0103 for common epithelial tumors, as well as PDS0202, a universal influenza vaccine candidate in infectious disease, and generates revenue through equity and debt financing while pursuing clinical development and regulatory approvals.